Home › Research › Prevention trials
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Chuang‐Kuo Wu, Jong‐Ling Fuh. Journal of the Chinese Medical Association, 2025-05-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with a continuum of stages ranging from preclinical/asymptomatic phase to severe dementia. Over the past decades, significant advances in diagnostic biomarkers and disease-modifying therapies have reshaped the treatment landscape. This review provides a comprehensive overview of the current treatment paradigm for AD in 2025, incorporating the latest developments in pharmacological and non-pharmacological interventions. The advent of anti-amyloid immunotherapy, including the US Food & Drug Administration (FDA)-approved monoclonal antibodies such as lecanemab and donanemab, has proven efficacy in slowing cognitive decline in early-stage AD. These therapies mark a change in thinking in AD management, emphasizing the importance of early diagnosis and intervention. Cholinesterase inhibitors and memantine remain the standard treatments for mild, moderate to severe dementia, providing symptomatic relief and functional stabilization. Additionally, emerging strategies targeting tau pathology and neuroinflammation are under investigation, offering hope for future breakthroughs. Beyond pharmacotherapy, this review highlights the importance of personalized, multimodal treatment approaches that integrate lifestyle modifications, cognitive training, and caregiver support. The updated diagnostic framework, incorporating fluid and imaging biomarkers, enables more precise staging and individualized treatment plans. Despite these advances, challenges still lie in refining patient selection, addressing treatment-related side effects, and ensuring accessibility to appropriate therapies. As the field moves forward, ongoing clinical trials and real-world evidence will further refine treatment strategies. A proactive approach, combining early detection with disease-modifying and symptomatic therapies, is essential for improving patient outcomes and quality of life. This article synthesizes current knowledge and provides a roadmap for clinicians and researchers navigating the evolving landscape of AD treatment.
What this study adds
Evidence grade: Low
This review describes current treatment strategies for the Alzheimer's disease spectrum, including anti-amyloid immunotherapies such as lecanemab and donanemab that slow cognitive decline in early-stage disease, and standard symptomatic treatments. It reports that strategies targeting tau pathology and neuroinflammation are still under investigation, so no cure or prevention is established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wu, C., & Fuh, J. (2025). A 2025 update on treatment strategies for the Alzheimer’s disease spectrum. Journal of the Chinese Medical Association. https://doi.org/10.1097/jcma.0000000000001252
Vancouver
Wu C, Fuh J. A 2025 update on treatment strategies for the Alzheimer’s disease spectrum. Journal of the Chinese Medical Association. 2025. doi:10.1097/jcma.0000000000001252. PMID: 40442885.
BibTeX
@article{wu2025-40442885,
author = {Wu, Chuang‐Kuo and Fuh, Jong‐Ling},
title = {{A 2025 update on treatment strategies for the Alzheimer’s disease spectrum}},
journal = {Journal of the Chinese Medical Association},
year = {2025},
doi = {10.1097/jcma.0000000000001252},
pmid = {40442885},
url = {https://doi.org/10.1097/jcma.0000000000001252}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Over the past decades, significant advances in diagnostic biomarkers and disease-modifying therapies have reshaped the treatment landscape.
Why it matters
This review describes current treatment strategies for the Alzheimer's disease spectrum, including anti-amyloid immunotherapies such as lecanemab and donanemab that slow cognitive decline in early-stage disease, and standard symptomatic treatments. It reports that strategies targeting tau pathology and neuroinflammation are still under investigation, so no cure or prevention is established.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the Chinese Medical Association) |
| Journal's citation record | 0 / 4 | Journal of the Chinese Medical Association: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 70 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 23.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 38.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 3 / 4 | Cited 70 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jong‐Ling Fuh: h-index 79 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Brown University: institution h-index 1,120 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40442885) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/jcma.0000000000001252
- PubMed: 40442885
- Original source →
- Free full text: Journal of the Chinese Medical Association →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Prevention trials from nearby years
Also in Prevention trials
91 studies in the library are filed under Prevention trials with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention trials hub.